Castleview Partners’s BioNTech BNTX Stock Holding History

Castleview Partners’s Portfolio BNTX Stock Details BNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-520,240	Closed	-$2.02K	–	747
2021 Q4	$2.02K	Buy	+520,240	New	+$142M	0.02%	281
2021 Q2	$161K	Buy	+719	New	+$136K	0.07%	236

Other funds holding BNTX

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Pendal Group Sydney, Australia $11.6B AUM 12.87% 1-Year Est. Return

Flossbach Von Storch Cologne, Germany $21.4B AUM 8.31% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fosun International Hong Kong, China $399M AUM 16.11% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Castleview Partners's BNTX Position: Q1 2022 in Review

Castleview Partners sold out of BioNTech (BNTX) in Q1 2022, closing a stake of 520,240 shares — an estimated $2.02K sold.

Castleview Partners first reported a position in BNTX in Q2 2021 and held it in 2 quarters. The position peaked at $161K in Q2 2021. 287 funds tracked by Wall St. Rank hold BNTX as of Q1 2022.

Castleview Partners reported no remaining BioNTech position as of Q1 2022 after selling out during the quarter.
Castleview Partners sold 520,240 BioNTech shares in Q1 2022, an estimated $2.02K.
Castleview Partners first reported a position in BioNTech in Q2 2021 and held it in 2 quarters.
Castleview Partners's BioNTech position peaked at $161K in Q2 2021.
287 funds tracked by Wall St. Rank held BioNTech as of Q1 2022.

Based on Castleview Partners's 13F filing for Q1 2022, filed 16 May 2022.